To the Editor Cohen et al1 reported the efficacy and safety results of switching from natalizumab to fingolimod in patients with multiple sclerosis in a real-practice setting in the ENIGM (Enquête Nationale sur I’Introduction du Fingolimod en Relais au Natalizumab) study. We read the article with great interest; however, we are afraid that some of the presented results may not be conclusively supported by the analyses that were performed.
Bianco A, Rossini PM, Mirabella M. Moving to Fingolimod From Natalizumab in Multiple Sclerosis: The ENIGM Is Not Solved. JAMA Neurol. 2014;71(7):924-925. doi:10.1001/jamaneurol.2014.1135